Long term outcomes of intracarotid arterial transfusion of circulatory-derived autologous CD34 + cells for acute ischemic stroke patients—A randomized, open-label, controlled phase II clinical trial

Table 2 Circulatory hematologic findings

Variables	Cell-treated group (n = 14)	Control group (n = 14)	p value‡
Baseline prior to G-CSF treatment
Red blood cells (RBC) (× 10⁶)	4.98 ± 0.60	4.49 ± 0.56	0.036
White blood cells (WBC) (× 10³)	8.7 ± 2.2	8.9 ± 3.8	0.866
Hemoglobin (g/dL)	14.6 ± 1.4	13.3 ± 1.7	0.033
Platelet (× 103/µL)	237.6 ± 52.3	270.9 ± 134.9	0.398
Segment (%)	72.8 ± 9.4	69.9 ± 8.3	0.395
Lymphocyte (%)	18.9 ± 8.4	19.6 ± 6.6	0.804
Compared prior to & after G-CSF treated*	Baseline†	After G-CSF treated†
Red blood cells (× 10⁶)	4.98 ± 0.60	4.58 ± 0.57	< 0.001
White blood cells (× 10³)	8.7 ± 2.2	49.6 ± 12.1	0.005
Hemoglobin (g/dL)	14.6 ± 1.4	13.5 ± 1.2	< 0.001
Platelet (× 10³/µL)	237.6 ± 52.3	228.4 ± 67.9	0.068
Segment (SEG) (%)	72.8 ± 9.4	81.8 ± 4.4	0.408
Lymphocyte (LYM) (%)	18.9 ± 8.4	7.0 ± 2.7	0.553
HPCs (× 10³/µL)	–	92.8 ± 208.4	–

^*Indicated granulocyte colony stimulating factor (G-CSF) was only administered to the cell-treated group by subcutaneous administration (5 μg/kg twice a day for 4 days)
^†Indicated the parameters of prior to and after G-CSF treatment in group 1 patients
HPCs hematopoietic progenitor cells
^‡Indicated by independent t test or t test for paired data

ISSN: 1757-6512